Immupharma PLC - Chairman’s Open Letter to Shareholders
RNS REACH |

ImmuPharma PLC
("ImmuPharma" or the "Company")
Chairman's Open Letter to Shareholders
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman,
Dear Shareholders
I wanted to take this opportunity, on behalf of the ImmuPharma Board, to thank you for your strong support at this week's General Meeting, where both resolutions relating to the proposed Lanstead placing and WRAP retail offering were approved. Resolution 1 received 91.46% support and Resolution 2 received 88.91%, reflecting clear shareholder endorsement of the Company's corporate strategy, as outlined in our announcement of
The approval of these resolutions enables us to complete the fundraising, comprising a
Our primary focus remains on securing a value-enhancing partnering agreement for our lead auto-immune technology platform, P140, during 2026. Recent progress continues to reinforce both the scientific rationale and commercial positioning of this program, and the management team is actively engaged in progressing discussions toward this objective.
The P140 update, issued on
Following the General Meeting, we are now investing in our second key asset, Kapiglucagon, for type 1 diabetes. We have kickstarted an accelerated development program with a clear two-year plan, which was outlined in the recent Investor Meet Company presentation (https://www.immupharma.co.uk/updates/interviews/).The funding secured is structured to support this program, and we expect to announce regular progress updates over the next two years, as Kapiglucagon advances through its development program and towards potential partnering opportunities.
The structure of the Lanstead subscription provides a mechanism through which the Company may potentially benefit from future share price performance, with the 8p Benchmark Price acting as the reference point for returns under the Sharing Arrangement. The Board therefore believes that continued operational progress and news flow relating to P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.
Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities.
With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.
We look forward to updating you further on our progress.
Yours sincerely,
Chairman
For further information, please contact:
|
ImmuPharma PLC (www.immupharma.co.uk)
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
SPARK Advisory Partners Limited (NOMAD)
|
+44 (0) 203 368 3550 |
|
Stanford Capital Partners (Joint Broker) |
44 (0) 20 3650 3650
|
|
Capital (Joint Broker)
|
+44 (0) 1483 413500 |
Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS of
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895
Notes:
* Based on the assumption that the total level of receipts under the 2026 Lanstead Agreement (which are variable and depend upon the level of the Company's Measured Price versus the Benchmark Price each month) will be equal to the Subscription of
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE